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Abstract
Background: The prediction of the public health impact of a preventive strategy provides valuable support for decision-
making. International guidelines for hypertension management have introduced the level of absolute cardiovascular risk in
the definition of the treatment target population. The public health impact of implementing such a recommendation has
not been measured.
Methodology/Principal Findings: We assessed the efficiency of three treatment scenarios according to historical and
current versions of practice guidelines on a Realistic Virtual Population representative of the French population aged from
35 to 64 years: 1) BP$160/95 mm Hg; 2) BP$140/90 mm Hg and 3) BP$140/90 mm Hg plus increased CVD risk. We
compared the eligibility following the ESC guidelines with the recently observed proportion of treated amongst
hypertensive individuals reported by the Etude Nationale Nutrition Sante ´ survey. Lowering the threshold to define
hypertension multiplied by 2.5 the number of eligible individuals. Applying the cardiovascular risk rule reduced this number
significantly: less than 1/4 of hypertensive women under 55 years and less than 1/3 of hypertensive men below 45 years of
age. This was the most efficient strategy. Compared to the simulated guidelines application, men of all ages were
undertreated (between 32 and 60%), as were women over 55 years (70%). By contrast, younger women were over-treated
(over 200%).
Conclusion: The global CVD risk approach to decide for treatment is more efficient than the simple blood pressure level.
However, lack of screening rather than guideline application seems to explain the low prescription rates among
hypertensive individuals in France. Multidimensional analyses required to obtain these results are possible only through
databases at the individual level: realistic virtual populations should become the gold standard for assessing the impact of
public health policies at the national level.
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Introduction
The evolving complexity of guidelines of cardiovascular
prevention
The prediction of the health impact of a therapeutic strategy on
a population is of growing importance to help decision-making in
the prescription process and raises a number of technical issues
[1]. Although cardiovascular mortality has decreased in the last
decades in France, it stands second in mortality statistics [2], which
explains why cardiovascular prevention remains one of the major
challenges for health authorities.
Before the first recommendations for the prevention of coronary
heart disease elaborated by the ESC, the European Atherosclerosis
Society, and the European Society of Hypertension were
published in 1994 [3], there was a plethora of confusing national
and international guidelines for the prevention of CVD. The
prescription of drugs was based on a univariate approach,
assuming that all the benefit from treatment was explained by
lowering a single risk factor. Historically, the threshold accepted to
define hypertension was 160/95 mm Hg [4] until the new
threshold of 140/90 mm Hg was adopted in the early 1990s by
the international societies for the management of hypertension
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17508[4,5]. As new evidence on the benefit from blood pressure
lowering drugs on the incidence of cardiovascular events became
available, the focus of preventive interventions changed to put
emphasis on global cardiovascular risk management [3,6,7].
Although the estimation of total cardiovascular risk to guide
patient management has been encouraged by the European
guidelines since their first edition, [3] a quantitative estimate of
global cardiovascular risk at the individual level was formally
introduced only on 2003. Since then, the ESC practice guidelines
recommend integrating the risk predicted using a multivariate
model adapted to European populations [8] in the treatment
decision [7]. The proposed risk equation, called SCORE, is based
on data from 12 European cohorts, with 205178 individuals
examined at baseline between 1970 and 1988, representing 2.7
million years of follow-up and 7934 cardiovascular deaths. The
SCORE equation estimates the individual probability of experi-
encing cardiovascular death over 10-years resulting from combi-
nations of covariates such as age, gender, blood pressure, total
cholesterol, smoking habit and diabetic status. This change in the
guideline paradigm has an intuitively obvious rationale, which is:
the higher the risk, the greater the benefit from prevention,
assuming the benefit to be proportional to the baseline risk.
However, such a change increased drastically the complexity of
the guidelines, transforming their application into a multidimen-
sional problem.
Are guidelines for cardiovascular prevention in
hypertensives applied in France?
The paucity of information regarding hypertension manage-
ment in France makes it difficult to explore the impact of
recommendations on the health of the population. A few studies
have revealed that the cardiovascular risk of hypertensive patients
is not regularly assessed in daily practice and that when measured
it does not influence physicians’ practices, since the prescription of
medications is mostly based on the blood pressure level of their
patients [9].
Modelling approaches as a solution to address the issue
of complexity
A modelling approach has been used to quantify the treatment
effect at the population level, looking at the impact of different
strategies based on summarized data [10]. Working at the average
level enables to reach some objectives, such as the cost
effectiveness of different drug strategies in a given population.
However, this approach is unable to deal with the multidimen-
sional nature of the current guidelines, which are based both on
risk and on risk factor levels.
Marshall and Rousse [11] used a hypothetical population at the
general practice level to simulate and compare the impact and cost
effectiveness of different screening strategies for cardiovascular
prevention based on a multidimensional approach, which
integrated risk factors and risk levels. In the present paper, we
extend their approach, using a Realistic Virtual Population (RVP)
representative of the French population [12]. We explore the
impact of administering blood pressure lowering drugs to
individuals of this virtual population, considered separately by
gender and age categories, following specific multidimensional
rules as defined in practice guidelines. Our objectives were to
assess the public health impact of implementing historical and
current guidelines, and to explore whether the current ones were
applied in France. We provide here an estimate of the impact in
terms of the number of events prevented (NEP) by treatment and
of the efficiency, measured as the number of eligible subjects in the
number of events prevented (NES/NEP ratio), for three different
scenarios to select the individuals eligible for treatment. The results
of a comparison between the theoretical implementation of
current guidelines in the RVP and the observed prescriptions
reported by the Etude Nationale Nutrition Sante ´ (ENNS), suggest
important discrepancies between the prescription of antihyperten-
sive medications in France and the ESC-ESH recommendations.
Results
Simulated administration of antihypertensive treatment
The public health impact of the different scenarios in terms of
NEP is presented in figure 1. Scenario II prevented twice as many
accidents as scenario I; scenario III prevented a similar number of
accidents as scenario II. Table 1 provides the proportion of eligible
subjects in each category of age and gender and the efficiency of
each scenario. Overall, the first scenario resulted in treating 12.4%
of individuals; the second scenario multiplied by 2.5 the number of
eligible individuals of the former, putting 31.1% of the whole
population on treatment. The lower efficiency of this strategy is
illustrated by the elevated NES/NEP ratio. The third scenario,
integrating the absolute risk criterion, presented the smallest NES/
NEP ratio. It reduced to 20.0% the number of eligible subjects,
with a few women eligible for treatment under age 55 years and
men under age 45 years.
The theoretical guidelines implementation and the
observed prescriptions
The prevalence of hypertension estimated in the virtual
untreated individuals from the RVP was lower than that reported
by ENNS in all age-sex categories except for men aged 35–44
years; and when reconstituted by integrating the information from
the treated hypertensive individuals of the MONICA survey, it
was higher in all categories except for men aged 55–64 years. Not
taking into account treated individuals from MONICA did not
significantly change the basic proportion of hypertensive individ-
uals in the RVP, which was similar to that reported by ENNS
(Figure 2). The number of treated hypertensive subjects in ENNS
was low in all men and in women aged 55 to 64 years compared to
the hypertensive subjects of the RVP that would be eligible for
treatment according to guidelines (Figure 3). The virtual
application of recommendations led to striking different propor-
tions of eligible hypertensive individuals related to gender,
resulting from the differences in absolute cardiovascular risk
between men and women. No such differences were observed in
ENNS.
Discussion
Lowering the threshold to define hypertension hugely increased
the potential costs of prevention, since it amplified the number of
French people eligible for treatment by 2.5. Surprisingly, the
impact of this ‘‘simple’’ shift in recommendations has never been
assessed before our work. On the other hand, applying the
predicted cardiovascular risk as recommended on the virtual
French population significantly reduced the number of subjects
eligible for treatment, especially among younger individuals
because of their low risk, and was the most efficient strategy.
Our simulations illustrated how taking into account the absolute
risk criterion to define the individuals eligible for treatment as in
the third scenario decreases drastically the number of individuals
to be treated in younger age classes (less than 1/3 of hypertensive
men under age 45 years and less than 1/4 of hypertensive women
under age 55 years) (Table 1, figure 3). Figure 3 also shows that
The Global Cardiovascular Risk Approach in France
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has already been suggested by the ESC guidelines [13]. This global
risk strategy, which makes treating older men preferentially
because they have the highest risk, is the most efficient among
the three strategies presented here, as suggested by its smallest
NES/NEP ratio. Applying this strategy implies, however, that
prescribers accept to exclude from cardiovascular prevention a
significant proportion of the population, which is relatively
protected due to age or gender. This illustration of the
consequences of the high-risk strategy should thus be seen as a
support for the need of complementary public health measures to
reduce population levels of risk factors and delay the occurrence of
cardiovascular events [13].
Despite their evident logic for optimising health resources, the
ESC recommendations do not appear to be applied in France.
The data on the observed prescription of antihypertensive
treatments reveal that French hypertensive men of all ages and
women over age 55 years are significantly undertreated with a
ratio treated over eligible between 32 and 70%, whereas before 55
years of age women are overtreated with a ratio of over 200%
when compared to our simulated application of guidelines
(Figure 3) [14]. On the other hand, the steep increase of the
eligibility proportion due to the well established risk differences
related to gender and age is not reflected by ENNS, where women
under 55 years are more treated than men, with a softer gradient
related to age in both men and women. Of note, the largely
predominant reason for not being treated is the lack of
hypertension recognition, which concerns more than 65% of
men under 55 years of age, leaving little room for the
recommended limitation of the prescription in low risk people.
These observations suggest that the absolute risk criterion is not
well taken into account when deciding whether or not to use
antihypertensive medications in current medical practice in
France.
Our approach presents certain limitations. The age range of the
RVP is restricted to 35–64 years. This was the age range in the
MONICA survey, whose data constitute the core of the simulated
RVP. Since the French population, as many others, is getting
older, the age spectrum of the RVP should be broadened to get
more comprehensive estimates of the possible consequences of
implementing these scenarios in a real setting.
The RVP is composed of untreated individuals, leading to an
underestimate of the prevalence of hypertension. We made this
choice for the sake of simplicity, because taking into account the
data of treated hypertensives in the late nineties in France [15]
would imply estimating their untreated blood pressure values,
introducing a source of uncertainty in the simulated population
and further estimates originating from it. However, it is unlikely
that differences in prevalence of this magnitude could modify
Figure 1. Gains from the simulation of different scenarios for treatment administration in the RVP. Points signal the number of events
prevented thanks to treatment in scenarios I to III for men and women in each age category. Horizontal bars indicate the median, and vertical lines
show the inter-quartile range of the predicted number of events.
doi:10.1371/journal.pone.0017508.g001
Table 1. Proportion of eligible subjects by age and gender
categories and efficiency of each scenario.
NES/N (%) NES/NEP
Age classes Men Women
Scenario I 35–44 10.9 3.7
SBP$160 or 45–54 18.0 8.5
DBP$95 mm Hg 55–64 22.3 14.2
Total 16.5 8.4 201
Scenario II 35–44 27.1 10.7
SBP$140 or 45–54 40.0 24.2
DBP$90 mm Hg 55–64 52.9 39.9
Total 38.7 23.7 243
Scenario III 35–44 7.2 1.6
ESC guidelines 45–54 32.1 6.4
implementation 55–64 49.1 35.6
Total 27.4 12.9 171
Abbreviations: NES, number of eligible subjects; N, size of each class;
NEP, number of events prevented.
doi:10.1371/journal.pone.0017508.t001
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the application of the CVD risk criterion, so we consider that this
limitation of the RVP does not minimize the relevance of our
results.
Relative risk of treatment was assumed to be constant. This may
not be true and induce a bias of the predicted public health impact
of the antihypertensive treatments. However, our main objective
was to illustrate the different impacts of each strategy designed to
identify the eligible individuals rather than to obtain an unbiased
estimation of the treatment effect. The choice of a constant relative
risk only simplified such a demonstration, without introducing new
sources of variability that could confound the interpretation of our
results.
We focused on cardiovascular death, but treatment benefit
concerns also non-fatal events such as stroke, or cardiac failure,
leading to a significant handicap. As non-fatal event rates depend
critically upon definitions and diagnostic methods, which vary
across different studies and with the development of new
Figure 2. Comparison of the prevalence of hypertension estimated in the RVP with that reported by ENNS. Bars represent the
percentage of hypertensive individuals in each category of age in both sexes separately, estimated in the RVP, the ENNS survey and the RVP after
reconstitution of data including the proportion of hypertensive subjects taking medications in the MONICA-France cohort. Abbreviations: RVPi, the
realistic virtual population initial estimates; ENNS, Etude Nationale Nutrition Sante ´; RVPr, the reconstituted estimates from the RVP.
doi:10.1371/journal.pone.0017508.g002
Figure 3. Theoretical eligibility from implementing the guidelines and treatment of hypertension in a real setting. Bars signal the
proportion of hypertensive individuals eligible and ineligible for treatment according to the ESC guidelines implemented in the RVP and the
proportion of hypertensive subjects that are unknown and untreated, those who are known but untreated and those who are treated in the ENNS
survey for each category of age in men and women. Results are expressed as a percentage of all the individuals belonging to each class.
doi:10.1371/journal.pone.0017508.g003
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guidelines advocates using preferably hard endpoints. In the
present work, we applied the SCORE risk equations because they
are more suitable for the French population than other available
risk predictors, as we have shown in a previous report [12]. It
would be desirable in future developments of our approach to
include separate estimates for relevant outcomes, which underlines
the need for high-quality data to build up suitable risk equations.
Our approach also presents original strengths. The important
increase in the number of subjects eligible for treatment resulting
from the change in the definition of hypertension, which has not
been explored before, is directly related to the shape of the
population distribution of blood pressure values: the magnitude of
this change may not be the same in all other populations.
In coronary prevention, a modelling strategy has been applied
to a hypothetical average patient with a known level of pre-
treatment risk, who received different preventive treatments.
Average estimates of costs and benefits associated with each
intervention allowed to rank them according to their incremental
cost effectiveness [10]. Estimates from this kind of approach are
safe only when the relationship between the underlying risk factor
and risk is linear, since the results computed from mean risk factors
should not differ from those of averaged individual risks. However,
this is not true for non-linear relationships, and the risk factor-
disease incidence relation is rarely linear [16]. We have decided to
work on data of each individual from the RVP, which can provide
a reliable estimate of both the distribution of risk factors and
cardiovascular risk. This approach makes it possible to take into
account the particular risk structure of the population, which is a
major advantage regarding the prediction of the public health
impact of a given strategy implemented in that population. In
addition, this individual data approach allows simulating complex
strategies using more than one unique dimension in terms of
decision threshold, as we did here in combining the level of risk,
the level of blood pressure and age in the decision rule. The degree
of definition of the data characterising the RVP allowed
considering precise levels of each dimension defining intermediate
categories of individuals. All these attributes of the RVP allow
precise estimation of the number of individuals who would be
concerned by a given therapeutic strategy and the potential costs
of implementing that strategy.
The results of this study confirm that a modelling and
simulation approach should be used in guiding public health
policies, since it allows quantification of the impact of diverse rules
for treatment administration before they are applied. Since the
global risk approach appears to be the best scenario in terms of the
benefit expected from the available health resources, the reasons
why it does not influence the prescription of antihypertensive
medications in France deserve further investigation.
Perspectives
Many developments of our approach are envisaged to provide
more complete estimates of the public health impact of treatment
strategies. These developments are: extending the age range of the
RVP, integrating the prediction of non-fatal events, regularly
updating the baseline characteristics and the rate of predicted
events with new information sources, taking into account
compliance and treatment effect modifiers, e.g. a different relative
risk in smokers. Using relevant therapeutic models could help to
Figure 4. Bivariate distributions in two virtual populations, simulated with and without taking into account their covariance.
Contour plots show the distribution of systolic and diastolic blood pressure on the X and Y axes, respectively. Bars beside plots indicate the scales of
colours representing the density of individuals at each level of bivariate values. Panel A, taking into account the covariance. Panel B, covariance=0.
doi:10.1371/journal.pone.0017508.g004
Table 2. Recommendation for use of blood pressure
lowering drugs according to the blood pressure level and the
level of risk.
SCORE No hypertension Hypertension
10-year CVD
risk Normal
High
normal Grade 1 Grade 2
Grade
3
Low No No No Drugs Drugs
if persists
Moderate No No Consider Drugs Drugs
drugs if persists
Increased No Consider Drugs Drugs Drugs
drugs
Markedly No Consider Drugs Drugs Drugs
Increased drugs
Schematic guidelines inspired from the table for ‘‘Management of total CVD risk
– blood pressure’’ appeared in the ESC guidelines on CVD prevention 2007 [13].
doi:10.1371/journal.pone.0017508.t002
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hypertensives, allowing their integration into the RVP. Such
therapeutic models could also be used to estimate precisely the
treatment effect in different settings. Further developments of our
approach include the exploration of alternative strategies to
optimise the identification of the treatment target population, and
the description of a method to design those strategies.
Materials and Methods
We analysed the impact and the efficiency [17] of three
strategies for administering blood pressure lowering drugs on a
realistic virtual French population, following different rules of
application chosen to illustrate the changes of guidelines over time.
We generated the RVP [11] using the age-sex structure from
official national statistics [18] to which we combined transversal
data concerning the cardiovascular risk factors distribution from
the MONICA-France survey [15]. This population survey of 3508
participants is the most representative study of cardiovascular risk
factors in the French population. It was conducted between 1995
and 1997 in the three French registries participating in the WHO-
MONICA project, including a population-based sample repre-
sentative of the 35 to 64 year-old population, stratified by age and
gender [19]. We used data from the untreated individuals
(n=2595) to generate the RVP through a multivariate normal
distribution [20], taking into account the covariance between these
characteristics. The risk distributions in different subgroups of the
population with clustered risk factors are thus more realistic, and
are prone to capture the important features of the risk structure of
the population. This realism is illustrated through the simulated
distributions of systolic and diastolic blood pressures, with and
without taking into account their co-variation (Figure 4). Each
individual was characterised by its age, gender, systolic and
diastolic blood pressure, total cholesterol, smoking and diabetic
status, from which we calculated the individual 10-year risk of fatal
cardiovascular events (CVD) using the updated version of the
SCORE equations for ‘‘low risk regions’’ [8,21].
The size of the working sample was defined on practical bases: a
sample size corresponding to 4% of the French population of the
same age and sex allowed both to run programs with small
computation time, and to obtain results with high enough precision.
Simulating different scenarios for treatment
administration
Virtual subjects were classified by gender and age categories of
10-year intervals. Three scenarios to select virtual subjects who
would receive the simulated treatment on each category of age and
sex were defined as follows:
N Scenario I, the earlier recommendation for treatment of
hypertension: Subjects having a SBP$160 or DBP$95 mm
Hg after 3 months of observation plus non-drug measures [4,5].
N Scenario II, the current definition of hypertension: Subjects
with a SBP$140 or DBP$90 mm Hg [4].
N Scenario III, the current ESC-ESH recommendation for CVD
prevention [13,22], applying the quantitative approach based on
the predicted global cardiovascular risk and blood pressure level
proposed by the ESC version of guidelines [13]. We included in
this definition all those individuals having an indication such as
‘consider drugs’ or ‘drugs if persists’ in the guidelines procedure
(Table 2). Thus, eligible subjects were those with stage 2 and 3
hypertension despite the level of CVD risk, stage 1 hypertension
plus CVD 10-year risk 1–4%, and those with high normal blood
pressure at increased risk (CVD risk $5%).
Size of target populations and public health impact for
each scenario
The relative size of the treatment target population is given by
the number of subjects eligible to treatment referred to the total
number of subjects in each age-sex category. The public health
impact corresponds to the number of cardiovascular deaths that
Figure 5. Procedure to determine the proportions eligible for
treatment and the number of CVD deaths prevented in each
treatment scenario. Abbreviations: CVD, cardiovascular death; NEP,
number of events prevented; NES, number of eligible subjects.
doi:10.1371/journal.pone.0017508.g005
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express the efficiency of each strategy, we divided the number of
eligible subjects by the number of events prevented (NES/NEP
ratio).
Treatment effect was represented by a relative risk of 0.83 for
fatal cardiovascular events for both men and women, derived from
a meta-analysis of the effect of antihypertensive treatments [24].
We assumed that relative risk remains constant across time. The
post-treatment risk is the initial CVD risk of each treated subject
multiplied by the relative risk. The number of events corresponds
to the sum of the individual risks with (NET) and without
(NEbaseline) treatment. NEP was estimated by subtracting the
number of events under treatment from the number of events that
would have occurred in the absence of any treatment in each
category of individuals.
The virtual application of guidelines and the observed
prescriptions in France
To examine whether the guidelines have influenced current
medical practice, we compared the proportion of hypertensives
from the RVP who were eligible to treatment according to
guidelines with the observed proportion of treated individuals from
the ENNS (Etude Nationale Nutrition Sante ´) survey [14]. This was
a cross-sectional survey conducted in France in 2006–2007. In this
study, blood pressure level, prevalence, awareness, treatment, and
control of hypertension were described in a sample of 2266 men
and women aged 18 to 74 years living in France. In order to check
the reliability of the results from the RVP, we first compared the
prevalence of hypertension estimated in the RVP according to its
current definition with that reported by ENNS in the age range 35
to 64 years. Since the RVP was built from data of untreated
individuals of the MONICA survey, we also included in this
comparison the prevalence of hypertension estimated in the RVP
reconstituted by taking into consideration the proportion of
hypertensives receiving treatment on each class of the MONICA
individuals.
An overview of the procedure used for the simulations is
provided in figure 5.
All the simulations and statistical analyses were performed using
R software, version 2. 7. 0 (2008) [25,26].
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